<DOC>
	<DOCNO>NCT00917904</DOCNO>
	<brief_summary>The purpose study determine whether dapivirine gel 4789 safe daily use healthy woman South Africa .</brief_summary>
	<brief_title>An Expanded Safety Study Dapivirine Gel 4789 Africa</brief_title>
	<detailed_description>To reduce influence adherence factor interpretation efficacy result , IPM consider use DOT ( Directly Observed Therapy ) base method vaginal microbicide gel delivery future Phase III study . IPM denote DOT base method Daily Monitored Adherence ( DMA ) . IPM014B Phase I/II study design : ( 1 ) ass compare safety daily application Dapivirine Gel 4789 , 0.05 % 2.5g matching vehicle placebo gel ; ( 2 ) ass acceptability daily application Dapivirine gel 4789 , 0.05 % 2.5g matching vehicle placebo gel ; ( 3 ) ass feasibility utilize DMA method large-scale phase III efficacy study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>1 . Women 18 40 year age inclusive give write informed consent 2 . Available visit consent follow procedure schedule study 3 . Agree daily application gel monitor per Daily Monitored Adherence ( DMA ) method 4 . Healthy selfreported sexually active 5 . HIVnegative determine HIV rapid test time enrollment 6 . On stable form contraception willing continue stable method contraception , OR , Have undergone surgical sterilisation least 3 month prior enrollment 7 . In absence use exogenous hormone ( ) , selfreported regular menstrual cycle define minimum 21 day maximum 36 day menses 8 . Upon pelvic/speculum examination colposcopy time enrollment , cervix vagina appear normal determined investigator 9 . Asymptomatic genital infection time enrollment 10 . Willing refrain use vaginal product object within 14 day prior enrollment duration study 11 . Willing answer acceptability adherence questionnaire throughout study 12 . Willing refrain participation research study duration study 13 . Willing provide adequate locator information study retention purpose reachable per local standard procedures 1 . Currently pregnant last pregnancy outcome within 3 month prior enrolment 2 . Currently breastfeed 3 . Participated research study within 60 day prior screen 4 . Previously participate HIV vaccine study 5 . Untreated urogenital infection ( either symptomatic asymptomatic ) within 2 week prior enrollment 6 . Presence abnormal physical finding vulva , vaginal wall cervix pelvic/speculum examination and/or colposcopy 7 . History significant urogenital uterine prolapse , undiagnosed vaginal bleeding , urethral obstruction 8 . Pap smear result screen require cryotherapy , biopsy , treatment ( infection ) , evaluation 9 . Any Grade 2 , 3 4 baseline haematology , chemistry urinalysis laboratory abnormality accord DAIDS Table Grading Adverse Experiences 10 . Unexplained , undiagnosed abnormal bleeding per vagina , bleed per vagina follow vaginal intercourse , gynaecologic surgery within 90 day prior enrollment 11 . Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex 12 . Any serious acute , chronic progressive disease 13 . Any condition ( ) , opinion investigator , might interfere adherence study requirement evaluation study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Healthy</keyword>
	<keyword>HIV seronegativity</keyword>
</DOC>